- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.09.24 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Guard Therapeutics International AB | 319 | GlobeNewswire | With effect from September 05, 2024, the subscription rights in Guard
Therapeutics International AB will be traded on First North Growth Market.
Trading will continue up until and including September... ► Artikel lesen | |
| 02.09.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.09.2024 | 456 | Xetra Newsboard | Das Instrument MSPA MA0000011488 ITISSALAT AL-MA. INH.DH 6 EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024 The instrument MSPA MA0000011488 ITISSALAT AL-MA.... ► Artikel lesen | |
| GUARD THERAPEUTICS INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 29.08.24 | Guard Therapeutics International AB: First patient dosed in Guard Therapeutics' phase 2b study POINTER | 167 | GlobeNewswire (Europe) | Guard Therapeutics today announced that the first patient has been dosed in the phase 2b clinical study POINTER with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.
"It... ► Artikel lesen | |
| 27.08.24 | Guard Therapeutics International AB: Guard Therapeutics carries out announced rights issue (repair issue) | 129 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, DISTRIBUTED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen |
4 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 54,58 | -0,51 % | Novonesis (Novozymes A/S): Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% | Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance... ► Artikel lesen | |
| GENMAB | 205,10 | -0,63 % | Genmab A/S: Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | Results from Arm 1 of the EPCORE NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,154 | +2,54 % | Arbutus Biopharma Aktie: Portfolioerweiterungen im Fokus | Die Arbutus Biopharma Corporation verzeichnete am 18. Januar 2025 eine leichte Abwärtsbewegung an der Börse. Der Aktienkurs des Biotech-Unternehmens sank um 0,62 Prozent auf 3,20 USD. Die Marktkapitalisierung... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,450 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 | - Received US Institutional Review Board (IRB) approval for pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) and engaged leading contract research... ► Artikel lesen | |
| VERICEL | 58,50 | +1,74 % | Beyond The Numbers: 5 Analysts Discuss Vericel Stock | ||
| SENSEI BIOTHERAPEUTICS | 0,524 | +3,15 % | Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones | - Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,339 | -0,09 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| MUSTGROW BIOLOGICS | 1,000 | +1,83 % | MustGrow Biologics Corp.: MustGrow Announces Closing of Private Placement of Units for $2,585,000 | Saskatoon, Saskatchewan--(Newsfile Corp. - January 16, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce the closing of the... ► Artikel lesen | |
| REGENXBIO | 7,150 | -1,38 % | REGENXBIO (NASDAQ:RGNX) Receives "Outperform" Rating from Royal Bank of Canada | ||
| AKEBIA | 2,250 | -0,88 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Jan. 2, 2025 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 6,050 | +10,00 % | Fennec Pharmaceuticals Inc (NASDAQ:FENC) Sees Large Decrease in Short Interest | ||
| ZEVRA THERAPEUTICS | 7,950 | +1,27 % | Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 | CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 3,500 | -0,57 % | Dermata Therapeutics: Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari with Daxxify | The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari with Daxxify® to treat primary axillary hyperhidrosis -If successful, the Companies may explore clinical development... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 4,980 | -0,80 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | BURLINGAME, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 19,300 | 0,00 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment... ► Artikel lesen |
Das Unternehmen GUARD THERAPEUTICS INTERNATIONAL AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,630 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GUARD THERAPEUTICS INTERNATIONAL AB finden Sie auf Wallstreet Online.
